![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhTsdZq4AuJAQteoZNj_cuRkF_jjXQgUnyDABOnCiBAHQpPwCxVpPCodFe3bI7PVB2WVCsPiX3qHlPw3HxF0_CjwsgOAf78J6uUyaTgD1kDhhZq-_9mgonYptyBFOolKAzt-Gq-JglnipFf/s320/a.png)
FDA asked for more data confirmed responses(tumor shrinkage) in the clinical programme using Rociletinib. Clovis has been highlighting combined response rates – that is, both confirmed and unconfirmed responses to the drug – in its public stats, but apparently FDA will only look at confirmed responses. The stats point to a confirmed response rate of 28% in 79 patients using 500mg dose and a 34% confirmed response rate in 170 patients using 625mg dose of rociletinib, competitor AstraZeneca’s Tagrisso’s confirmed response rate is 59%.
Clovis shares fell 70% in the US on Monday, and a further 11% on Tuesday. Monday’s fall must have spooked investors and took it out on Dishman.
How did Dishman Pharma take the hit because of Clovis Oncology?
Read more at http://capitalmind.in/2015/11/why-did-dishman-pharma-stocks-fall-by-14
No comments:
Post a Comment